Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.Abstract:
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...read more
Citations
More filters
Journal ArticleDOI
A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.
Peng Lin,Pengfei Yang,Shi Chen,You-You Shao,Lei Xu,Yan Wu,Wangsiyuan Teng,Xingzhi Zhou,Binghao Li,Chen Luo,Lei-Ming Xu,Mi Huang,Tianye Niu,Tianye Niu,Zhaoming Ye +14 more
TL;DR: The delta-radiomics nomogram incorporating the radiomics signature and clinical factors in this study could be used for individualized pathologic response evaluation after chemotherapy preoperatively and help tailor appropriate chemotherapy and further treatment plans.
Book ChapterDOI
Sarcomas of Soft Tissue and Bone.
TL;DR: The definition of soft tissue and bone sarcomas include a large group of several heterogeneous subtypes of mesenchymal origin that may occur at any age that often arise in adolescents and young adults.
Journal ArticleDOI
Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.
TL;DR: Wang et al. as mentioned in this paper evaluated the association of four CTLA-4 gene mutations, −1661A/G (rs4553808), −318C/T (rs5742909), +49G/A (rs231775), and CT60A/g (rs3087243), with osteosarcoma in the Chinese population.
Journal ArticleDOI
Late relapse of osteosarcoma: Implications for follow-up and screening
TL;DR: Reports of late relapse are rare as numbers are small, thus long‐term surveillance of patients is essential, and it is possible that sites of relapse are more unusual, and more extensive staging may be necessary when late relapse occurs.
Journal ArticleDOI
What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma
TL;DR: What is new regarding the roles of miRNAs in chondrosarcoma as well as the latest discoveries of identified mi RNAs in osteosarcomas are summarized.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.